AU2017317651B2 - Compounds for treating diseases associated with a mitochondrial dysfonction - Google Patents

Compounds for treating diseases associated with a mitochondrial dysfonction Download PDF

Info

Publication number
AU2017317651B2
AU2017317651B2 AU2017317651A AU2017317651A AU2017317651B2 AU 2017317651 B2 AU2017317651 B2 AU 2017317651B2 AU 2017317651 A AU2017317651 A AU 2017317651A AU 2017317651 A AU2017317651 A AU 2017317651A AU 2017317651 B2 AU2017317651 B2 AU 2017317651B2
Authority
AU
Australia
Prior art keywords
group
carbon atoms
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017317651A
Other languages
English (en)
Other versions
AU2017317651A1 (en
Inventor
Antoine Danchin
Patrice Garnier
Agnieszka Sekowska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stellate Therapeutics SAS
Original Assignee
Amabiotics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amabiotics SAS filed Critical Amabiotics SAS
Publication of AU2017317651A1 publication Critical patent/AU2017317651A1/en
Application granted granted Critical
Publication of AU2017317651B2 publication Critical patent/AU2017317651B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017317651A 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction Expired - Fee Related AU2017317651B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306094.0 2016-08-30
EP16306094.0A EP3290039B1 (en) 2016-08-30 2016-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction
PCT/EP2017/071812 WO2018041919A1 (en) 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction

Publications (2)

Publication Number Publication Date
AU2017317651A1 AU2017317651A1 (en) 2019-03-07
AU2017317651B2 true AU2017317651B2 (en) 2022-12-15

Family

ID=56896495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017317651A Expired - Fee Related AU2017317651B2 (en) 2016-08-30 2017-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction

Country Status (15)

Country Link
US (2) US10857135B2 (enExample)
EP (2) EP3290039B1 (enExample)
JP (1) JP7065854B2 (enExample)
KR (1) KR20200011927A (enExample)
CN (1) CN110035758B (enExample)
AU (1) AU2017317651B2 (enExample)
BR (1) BR112019004236A2 (enExample)
CA (1) CA3034694A1 (enExample)
ES (1) ES2800917T3 (enExample)
MA (1) MA46099A (enExample)
MX (1) MX394782B (enExample)
RU (1) RU2019108824A (enExample)
SG (1) SG11201901689YA (enExample)
WO (1) WO2018041919A1 (enExample)
ZA (1) ZA201900997B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction
JP2021517124A (ja) * 2018-03-07 2021-07-15 エーエムエーバイオティクス アルツハイマー病を治療するための化合物
US20220096574A1 (en) * 2019-01-29 2022-03-31 Holobiome, Inc. Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis
EP4028014A1 (en) * 2019-09-12 2022-07-20 Stellate Therapeutics Compounds for treating neurodegenerative diseases
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia
CN116850191A (zh) * 2023-06-16 2023-10-10 山东大学齐鲁医院 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用
WO2026057085A1 (zh) * 2024-09-15 2026-03-19 澳门科技大学 Queuine在抗衰老中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033703A2 (en) * 1995-04-25 1996-10-31 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
WO2016050804A1 (en) * 2014-09-29 2016-04-07 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936615A (ja) * 1982-08-24 1984-02-28 Takeda Chem Ind Ltd 発がん予防剤
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
FR3002139B1 (fr) * 2013-02-21 2015-06-19 Amabiotics Utilisation cosmetique de la queuine
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033703A2 (en) * 1995-04-25 1996-10-31 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
WO2016050804A1 (en) * 2014-09-29 2016-04-07 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Randerath, Cancer Research, vol. 44, 1167-1171, Mar. 1984. (Year: 1984). *

Also Published As

Publication number Publication date
BR112019004236A2 (pt) 2019-05-28
JP2019526634A (ja) 2019-09-19
EP3290039A1 (en) 2018-03-07
SG11201901689YA (en) 2019-03-28
US20210046056A1 (en) 2021-02-18
CN110035758A (zh) 2019-07-19
US10857135B2 (en) 2020-12-08
MA46099A (fr) 2019-07-10
MX394782B (es) 2025-03-24
ZA201900997B (en) 2020-05-27
ES2800917T3 (es) 2021-01-05
US11684611B2 (en) 2023-06-27
RU2019108824A (ru) 2020-10-01
CA3034694A1 (en) 2018-03-08
MX2019002369A (es) 2019-11-07
JP7065854B2 (ja) 2022-05-12
KR20200011927A (ko) 2020-02-04
EP3506903A1 (en) 2019-07-10
EP3290039B1 (en) 2020-03-25
CN110035758B (zh) 2023-06-16
RU2019108824A3 (enExample) 2020-12-31
WO2018041919A1 (en) 2018-03-08
AU2017317651A1 (en) 2019-03-07
US20190224174A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US11684611B2 (en) Compounds for treating diseases associated with a mitochondrial dysfunction
Ebrahimi-Fakhari et al. Protein degradation pathways in Parkinson’s disease: curse or blessing
ES2408785T3 (es) Nuevos enfoques terapéuticos para el tratamiento de CMT y trastornos relacionados
KR101964954B1 (ko) 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도
Jain-Vakkalagadda et al. Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea
Passemard et al. Endoplasmic reticulum and Golgi stress in microcephaly
CN111051316B (zh) 五环化合物
Kwon et al. Korean Red Ginseng and Rb1 facilitate remyelination after cuprizone diet-induced demyelination
WO2021048431A1 (en) Compounds for treating ataxia
JP4169597B2 (ja) 神経変性疾患の処置のためのトリペプチド及びトリペプチド誘導体
Kheradpezhouh et al. Salsolinol causing parkinsonism activates endoplasmic reticulum-stress signaling pathways in human dopaminergic SK-N-SH cells
CA3093212A1 (en) Compounds for treating alzheimer's disease
US20230040247A1 (en) Compounds for treating neurodegenerative diseases
Zhao et al. Extracellular vesicle-based bumetanide delivery alleviates depression-like behaviors of male mice by restoring chloride homeostasis
Chen et al. 20 (S)-protopanaxadiol targets brain-enriched adenylate kinase 5 to improve cognitive function via regulating hippocampal neural plasticity
US20250152660A1 (en) SCO-spondin-derived polypeptides for treating biological barriers dysfunction
WO2003045325A2 (en) Dopaminergic stimulatory factor
Balimane Characterizing the interactions of a non-peptide drug with the intestinal peptide transporter, hPEPT1
HK40022802A (en) Pentacyclic compound
HK40022802B (en) Pentacyclic compound

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee